Atrial fibrillation and thromboembolic risk in Greece

Hellenic Journal of Cardiology

Volumn 53, Issue 1, 2012, Pages 48-54

  Korantzopoulos, Panagiotis ^a   Andrikopoulos, George ^b   Vemmos, Kostas ^c   Goudevenos, John A ^a   Vardas, Panos E ^d  

^a UNIVERSITY OF IOANNINA   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c ALEXANDRA HOSPITAL   (Greece)

^d UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Anticoagulation; Atrial fibrillation; Greece; Stroke; Thromboembolic events

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; GENDER; GREECE; HEART ATRIUM FIBRILLATION; HUMAN; REVIEW; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; GREECE; HUMANS; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM;

EID: 84856269367     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Vardas PE, Mavrakis HE. Atrial fibrillation: a symptom treated as a disease? Hellenic J Cardiol. 2006; 47: 191-193.
2. Kannel WB, Benjamin EJ. Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin. 2009; 27: 13-24, vii.
3. Andrikopoulos GK. The Hellenic Heart Foundation. Interview by Robert Short. Circulation. 2007; 116: f129-131.
4. Nieuwlaat R, Connolly SJ. Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes. Heart. 2009; 95: 95-97.
5. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857-867.
6. Korantzopoulos P, Kolettis TM, Goudevenos JA, Siogas K. Errors and pitfalls in the non-invasive management of atrial fibrillation. Int J Cardiol. 2005; 104: 125-130.
7. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31: 2369-2429.
8. Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006; 27: 3018-3026.
9. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010; 123: 638-645. e4.
10. Deplanque D, Leys D, Parnetti L, et al. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol. 2004; 57: 798-806.
11. Ingelgård A, Hollowell J, Reddy P, Gold K, Tran K, Fitzmaurice D. What are the barriers to warfarin use in atrial fibrillation?: Development of a questionnaire. J Thromb Thrombolysis. 2006; 21: 257-265.
12. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007; 370: 493-503.
13. Goudevenos JA, Vakalis JN, Giogiakas V, et al. An epidemiological study of symptomatic paroxysmal atrial fibrillation in northwest Greece. Europace. 1999; 1: 226-233.
14. Ninios I, Bogossian H, Zarse M, et al. Prevalence, clinical correlates and treatment of permanent atrial fibrillation among the elderly: insights from the first prospective population-based study in rural Greece. J Thromb Thrombolysis. 2010; 30: 90-96.
15. Vemmos KN, Bots ML, Tsibouris PK, et al. Stroke incidence and case fatality in southern Greece: the Arcadia stroke registry. Stroke. 1999; 30: 363-370.
16. Vemmos KN, Takis CE, Georgilis K, et al. The Athens stroke registry: results of a five-year hospital-based study. Cerebrovasc Dis. 2000; 10: 133-141.
17. Vassilikos VP, Mantziari A, Goudis CA, et al. Differences in management of atrial fibrillation between cardiologists and non-cardiologists in Greece. Hellenic J Cardiol. 2010; 51: 113-121.
18. Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas I, Stefanadis C. Prevalence and five-year incidence (2001-2006) of cardiovascular disease risk factors in a Greek sample: the ATTICA study. Hellenic J Cardiol. 2009; 50: 388-395.
19. Mariolis A, Mihas C, Alevizos A, et al. Dissatisfaction with cardiovascular health and primary health care services: Southern Mani, isolated area in Europe. A case study. Hellenic J Cardiol. 2008; 49: 139-144.
20. Geitona M, Hollandezos M, Souliotis K, Athanasakis K, Kyriopoulos J. Cost-minimisation analysis of oral anticoagulant therapy monitoring methods: the case for prothrombin time self-monitoring. Hellenic J Cardiol. 2008; 49: 388-396.
21. Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol. 2009; 2: 474-480.
22. Sinha AM, Diener HC, Morillo CA, et al. Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): design and rationale. Am Heart J. 2010; 160: 36-41. e1.
23. Lim HS, Lip GY. Asymptomatic atrial fibrillation on device interrogation. J Cardiovasc Electrophysiol. 2008; 19: 891-893.
24. Michelena HI, Powell BD, Brady PA, Friedman PA, Ezekowitz MD. Gender in atrial fibrillation: Ten years later. Gend Med. 2010; 7: 206-217.
25. Volgman AS, Manankil MF, Mookherjee D, Trohman RG. Women with atrial fibrillation: Greater risk, less attention. Gend Med. 2009; 6: 419-432.
26. Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006; 37: 447-451.
27. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367: 1903-1912.
28. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009; 360: 2066-2078.
29. Bover R, Pérez-Góméz F, Maluenda MP, et al. Long-term follow-up of atrial fibrillation patients in the NASPEAF study. Prospective evaluation of different antiplatelet treatments. Rev Esp Cardiol. 2009; 62: 992-1000.
30. Pipilis A, Lazaros G, Tsakonas G, Stefanadis C. Triple antithrombotic therapy with aspirin, a thienopyridine derivative plus oral anticoagulation in patients with atrial fibrillation undergoing coronary stenting. Hellenic J Cardiol. 2010; 51: 330-337.
31. Zhao HJ, Zheng ZT, Wang ZH, et al. "Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest. 2011; 139: 260-270.
32. Lip GY, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010; 31: 1311-1318.
33. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151.
34. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011; 154: 1-11.
35. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-891.
36. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-992.
37. Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thromb Haemost. 2011; 105: 574-578.